# Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

> **NCT00257881** · PHASE1 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 46 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** CMD-193

## Key facts

- **NCT ID:** NCT00257881
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 46 (—)
- **Last updated:** 2007-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257881, "Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00257881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*